Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study.

ABSTRACT:

Background

The present single-center clinical trial was designed to evaluate the potential benefits of L-carnitine supplementation in patients with COVID-19 disease.

Methods and patients

The study was conducted on 75 patients with mild-to-moderate COVID-19 hospitalized in Shahid Beheshti Hospital-Hamadan, IRAN. The participants were randomly divided into intervention (n = 32) and control groups (n = 43). The control group received their standard hospital treatment only. In addition to standard medications, the intervention group received 3000 mg oral L-carnitine daily in three divided doses for five days. The blood samples were collected and para-clinical parameters were measured at the beginning and end of the treatment. Clinical outcomes were also recorded, and data were a

SUBMITTER: Talebi SS 

PROVIDER: S-EPMC9395946 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature